Main Products / Services
Marker X Multi-Cancer Early Detection Service.
1. Marker X Utilizes high-resolution mass spectrometry to analyze protein expression and modifications, coupled with ~3000 clinical blood samples, AI machine learning, and multi-indicator algorithm, a novel and efficient cancer indicator has been developed. 2. Cancer proteomic profiles for lung cancer, colorectal cancer, breast cancer, and esophageal cancer have been successfully established, with an accuracy exceeding 95% for early-stage cancer. 3. With a mere 3 mL blood draw, test results can be obtained within 10 days. 4. The sensitivity of the examination encompasses the earliest stages of carcinoma in situ and first-stage cancer. In comparison to other tests, cancer proteomics more accurately reflects the current physiological state, thereby reducing the risk of misdiagnosis.
Business Interests
1. Out Licensing: Early Cancer Detection Platform Technology Licensing. 2. Collaborative R&D: Collaborating with Medical Centers, Hospitals, and Clinics to Develop Precision Cancer or Other Disease Screening Services. 3. LDTs & IVD: Laboratory Services for Early Cancer Screening and Developing IVDs 4. Cross-Industry Collaboration: Integrating Services with the Insurance Industry.
Contact Info
Leo Huang
CEO
+886-960-364-146
leohuang@marker-x.com